he3235
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00716794)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C- Mol. weight
- 316.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545237 ↗
Also known as
- 17alpha-ethynyl-5alpha-androstane-3alpha,17beta-diol
- 17-ethynylandrostane-3,17-diol
- he3235
- he3235
- he3235
- he3235
- he 3235
- he-3235
- he-3235
- he-3235
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00716794 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | Harbor Therapeutics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harbor Therapeutics | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1